Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 43 Records) |
| Query Trace: Polycythemia Vera and BCR[original query] |
|---|
| TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings. BioMed research international 2013 2013 929840. Patriarca Andrea, Colaizzo Donatella, Tiscia Gianluca, Spadano Raffaele, Di Zacomo Silvia, Spadano Antonio, Villanova Ida, Margaglione Maurizio, Grandone Elvira, Dragani Alfre |
| [Detection and clinical significance of JAK2 V617F mutation in Chinese and Uyghur patients with chronic myeloproliferative in Xinjiang]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2012 Dec 33 (12): 12. Zhang XY, Maimaitili Y, Li Y, An L, Mao M, Fu L, Baier M, Wang XM |
| The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms. American journal of clinical pathology 2015 Jul 144 (1): 165-71. Lin Yani, Liu Enbin, Sun Qi, Ma Jiao, Li QingHua, Cao Zeng, Wang Jun, Jia Yujiao, Zhang Hongju, Song Zhen, Ai Xiaofei, Shi Lihui, Feng Xiaofang, Li Chenwei, Wang Jianxiang, Ru K |
| JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients. International journal of laboratory hematology 2015 Oct 37 (5): 654-60. Macedo L C, Santos B C, Pagliarini-E-Silva S, Pagnano K B B, Rodrigues C, Quintero F C, Ferreira M E, Baraldi E C, Ambrosio-Albuquerque E P, Sell A M, Visentainer J E |
| Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015 Oct . Krahling Tunde, Balassa Katalin, Kiss Katalin P, Bors Andras, Batai Arpad, Halm Gabriella, Egyed Miklos, Fekete Sandor, Remenyi Peter, Masszi Tamas, Tordai Attila, Andrikovics Hajnal |
| Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget 2016 Jul . Min-Gu Kang, Hyun-Woo Choi, Jun Hyung Lee, Yong Jun Choi, Hyun-Jung Choi, Jong-Hee Shin, Soon-Pal Suh, Szardenings Michael, Hye-Ran Kim, Myung-Geun Sh |
| Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2016 Jun 32 (Suppl 1): 112-6. Rashid Munazza, Ahmed Rifat Zubair, Ahmed Shariq, Nadeem Muhammad, Ahmed Nuzhat, Shamsi Tahir Sult |
| The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms. Blood cells, molecules & diseases 2016 Jul 59 25-30. Berzoti-Coelho Maria Gabriela, Ferreira Aline Fernanda, de Souza Nunes Natalia, Pinto Mariana Tomazini, Júnior Maurício Cristiano Rocha, Simões Belinda Pinto, Martínez-A Carlos, Souto Elizabeth Xisto, Panepucci Rodrigo Alexandre, Covas Dimas Tadeu, Kashima Simone, Castro Fabíola Att |
| Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype? Asian Pacific journal of cancer prevention : APJCP 2016 17 (3): 923-6. Ahmed Rifat Zubair, Rashid Munazza, Ahmed Nuzhat, Nadeem Muhammad, Shamsi Tahir Sult |
| The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms. PloS one 2016 11 (4): e0154183. Chen Yan, Fang Fang, Hu Yang, Liu Qian, Bu Dingfang, Tan Mei, Wu Liusong, Zhu Pi |
| Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms. Hematology (Amsterdam, Netherlands) 2016 Oct 21 (9): 520-5. Trifa Adrian P, Banescu Claudia, Dima Delia, Bojan Anca S, Tevet Mihaela, Moldovan Valeriu G, Vesa ?tefan C, Murat Meilin, Pop Ioan V, Skrypnyk Cristina, Popp Radu |
| Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. Blood cells, molecules & diseases 2016 Mar 57 54-7. Macedo Luciana Conci, de Cesare Quintero Fernanda, Pagliari-E-Silva Sara, Pagnano Katia Borgia Barbosa, Rodrigues Camila, de Alencar Josiane Bazzo, Sell Ana Maria, Visentainer Jeane Eliete Lagui |
| Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Annals of hematology 2016 Dec . Lekovic Danijela, Gotic Mirjana, Skoda Radek, Beleslin-Cokic Bojana, Milic Natasa, Mitrovic-Ajtic Olivera, Nienhold Ronny, Sefer Dijana, Suboticki Tijana, Buac Marijana, Markovic Dragana, Diklic Milos, Cokic Vladan |
| Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing. American journal of clinical pathology 2016 Oct 146 (4): 448-55. Gardner Juli-Anne, Peterson Jason D, Turner Scott A, Soares Barbara L, Lancor Courtney R, Dos Santos Luciana L, Kaur Prabhjot, Ornstein Deborah L, Tsongalis Gregory J, de Abreu Francine |
| Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients. Hematology (Amsterdam, Netherlands) 2017 Apr 1-8. Limsuwanachot N, Rerkamnuaychoke B, Chuncharunee S, Pauwilai T, Singdong R, Rujirachaivej P, Chareonsirisuthigul T, Siriboonpiputtana |
| CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology (Amsterdam, Netherlands) 2017 Oct 1-4. Ojeda Mara Jorgelina, Bragós Irma Margarita, Calvo Karina Lucrecia, Williams Gladis Marcela, Carbonell María Magdalena, Pratti Arianna Flav |
| [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases]. Zhongguo shi yan xue ye xue za zhi 2018 Aug 26 (4): 1122-1128. Li Zhen-Ling, Gao Li, Zhang Hui, Zhang Chun-Xia, Chen Yan-Rong, Huang Fan-Zhou, Gong Ming, Gao Ya-Yue, Tang Yin, Ma Yi-G |
| GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms. Annals of laboratory medicine 2018 Jul 38 (4): 296-305. Yang Naery, Park Sholhui, Cho Min Sun, Lee Miae, Hong Ki Sook, Mun Yeung Chul, Seong Chu Myong, Huh Hee Jin, Huh Jungw |
| Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes, chromosomes & cancer 2019 7 59 (1): 30-39. Courtier Frédéric, Garnier Séverine, Carbuccia Nadine, Guille Arnaud, Adélaide José, Chaffanet Max, Hirsch Pierre, Paz Damien Luque, Slama Bohrane, Vey Norbert, Ugo Valérie, Delhommeau François, Rey Jérome, Birnbaum Daniel, Murati An |
| Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC cancer 2019 6 19 (1): 590. Mejía-Ochoa Mónica, Acevedo Toro Paola Andrea, Cardona-Arias Jaiberth Anton |
| [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms]. Zhonghua nei ke za zhi 2019 12 59 (1): 35-39. Lyu X D, Li Y W, Guo Z, Xin Y P, Hu J Y, Fan R H, Song Y |
| Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. Hematology, transfusion and cell therapy 2019 Oct . Porto-Soares Moysés Antonio, de Oliveira Rafael Daltro, Cortopassi Gabriel Macedo, Machado-Neto João Agostinho, Palma Leonardo Carvalho, Figueiredo-Pontes Lorena Lobo |
| [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020 8 41 (7): 576-582. Tan Y X, Xu N, Huang J X, Wu W E, Liu L, Zhou L L, Liu X L, Yin C X, Xu D, Zhou |
| Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms. Blood cells, molecules & diseases 2020 3 82 102420. Keski Hak |
| A case of a primary myelofibrosis with progression and related literature review of progression phase genetics. International journal of laboratory hematology 2021 7 43 Suppl 1 78-81. Chen Dong, Fuda Franklin, Weinberg Ol |
| JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East. Iranian journal of pathology 2021 5 16 (2): 190-194. Safavi Moeinadin, Monabati Ahmad, Safaei Akbar, Mirtalebi Maryam Sadat, Faghih Masoum |
| Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India. Hematology/oncology and stem cell therapy 2021 3 15 (2): 13-20. Maddali Madhavi, Kulkarni Uday Prakash, Ravindra Niveditha, Arunachalam Arun Kumar, Venkatraman Arvind, Lionel Sharon, Manipadam Marie Therese, Devasia Anup J, Korula Anu, Fouzia N A, Abraham Aby, Srivastava Alok, George Biju, Balasubramanian Poonkuzhali, Mathews Vikr |
| Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges. Clinical lymphoma, myeloma & leukemia 2021 3 21 (6): e569-e578. Singh Suvir, Kaur Komalpreet, Paul Davinder, Jain Kunal, Singh Jagdeep, Narang Vikram, Garg Bhavna, Sood Neena, Dhillon Barjinderj |
| Thiol/Disulfide Balance in Older Patients with BCR-ABL Negative Myeloproliferative Neoplasms. Clinical laboratory 2021 12 67 (12): . Koyuncu Mahmut B, Cavusoglu Cagatay, Basir Hakan, Ilgan Mustafa, Ucar Mehmet A, Akdeniz Aydan, Tombak Anil, Tiftik Eyup N, Temel Gulhan O, Neselioglu Salim, Erel Ozc |
| Lab tests for MPN. International review of cell and molecular biology 2022 2 366 187-220. Moncada Alice, Pancrazzi Alessand |
- Page last reviewed:Feb 1, 2023
- Page last updated:Jun 02, 2023
- Content source: